United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine Rothblatt sold 3,833 shares of United Therapeutics Corp. stock on the open market in a transaction dated Thursday, January 30th. The shares were sold at an average price of $106.25, for a total value of $407,256.25. Following the completion of the sale, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $14,875. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of United Therapeutics Corp. from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, January 24th. They now have a $135.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Finally, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. United Therapeutics Corp. has an average rating of “Hold” and an average price target of $91.07.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.